Merck, Moderna Melanoma Vaccine Study Succeeds
Merck and Moderna announced positive results from a large late-stage trial of their personalized mRNA cancer vaccine, which significantly reduced the recurrence of melanoma, the deadliest form of skin cancer. Madison Muller reports on "Bloomberg Open Interest." (Source: Bloomberg)
We haven't written up this one. Bloomberg has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
- STAT+: Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial statnews.com
- Moderna and Merck Just Made History With the First mRNA Cancer Vaccine to Succeed in a Phase 3 Trial. Here's What That Means for Investors. fool.com
- Moderna, Merck mRNA cancer vaccine prevents melanoma from returning thehill.com
- Merck and Moderna say mRNA melanoma vaccine hits goals in late-stage trial cbc.ca
- Merck, Moderna declare Phase 3 success for personalized mRNA cancer vaccine endpoints.news
- Moderna and Merck's personalized skin cancer vaccine cleared its first large-scale trial qz.com
- Personalized cancer vaccine from Moderna, Merck shows promise in first late-stage melanoma trial cnbc.com
- Moderna and Merck Just Made History With the First mRNA Cancer Vaccine to Succeed in a Phase 3 Trial. Here's What That Means for Investors. nasdaq.com
